Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 120
- Registration Number
- NCT03295981
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸University of California - Los Angeles, Los Angeles, California, United States
🇺🇸Johns Hopkins University Hospital, Baltimore, Maryland, United States
Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2019-07-16
- Target Recruit Count
- 36
- Registration Number
- NCT03289338
- Locations
- 🇮🇳
Department of Endocrinology, PGIMER, Chandigarh, India
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Mohammed Milhem
- Target Recruit Count
- 17
- Registration Number
- NCT03173976
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Diagnosis of Osteogenesis Imperfecta in Children
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03169192
- Locations
- 🇪🇬
Assiut University, Assiut, Egypt
Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT03087851
- Locations
- 🇩🇰
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Denmark, Aarhus, Denmark
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
- Conditions
- Stage III Pancreatic Cancer AJCC v6 and v7Pancreatic AdenocarcinomaStage IB Pancreatic Cancer AJCC v6 and v7Stage IIA Pancreatic Cancer AJCC v6 and v7Recurrent Pancreatic CarcinomaStage I Pancreatic Cancer AJCC v6 and v7Stage IA Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7Stage IIB Pancreatic Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 44
- Registration Number
- NCT03073785
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03008447
- Locations
- 🇺🇸
Clinilabs, Inc, New York, New York, United States
🇺🇸NeuroTrials Research, Inc, Atlanta, Georgia, United States
🇺🇸Wake Research Assoicates, LLC, Raleigh, North Carolina, United States
Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Severance Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02784652
- Locations
- 🇰🇷
Severance hospital, Seoul, Korea, Republic of
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 89
- Registration Number
- NCT02739594
Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis
- Conditions
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2016-03-29
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02721940
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.